

Poster Program

Poster Session 1 Sunday 26 October, 18:00-19:00

[P1.01]	Adjuvants for inactivated poliomyelitis vaccines: Preclinical comparative studies Y.M. Vasiliev*, O.S. Kashirina, M.I. Chernikova, L.M. Khasanova, L.A. Kalmykova, <i>Mechnikov Research Institute of Vaccines and Sera, Russia</i>
[P1.02]	Development of processes for purification of Vi capsular polysaccharide from <i>Salmonella typhi</i> and O-specific polysaccharide from <i>Salmonella paratyphi A</i> for inclusion in a bivalent enteric fever vaccine S. Kothari*, N. Kothari, J. Kim, R. Carbis, <i>International Vaccine Institute, Republic of Korea</i>
[P1.03]	New vaccine against pertussis D. Hozbor*, D. Bottero, M.E. Gaillard, A. Errea, M. Ormazabal, E. Zurita, G. Moreno, E. Bartel, D. Flores, C. Castuma, <i>Universidad Nacional de La Plata, Argentina</i>
[P1.04]	Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles D. Hozbor*, M. Ormazabal, E. Bartel, M.E. Gaillard, D. Bottero, A. Errea, E. Zurita, G. Moreno, M. Rumbo, C. Castuma, <i>Universidad Nacional de La Plata, Argentina</i>
[P1.05]	The effect on hospital admissions of providing BCG vaccine at birth to low-birth-weight infants: Randomised trial in Guinea-Bissau F. Schaltz-Buchholzer*, S. Biering-Soerensen ^{1,2} , N. Lund ¹ , I. Monteiro ¹ , A. Andersen ² , A. Rodrigues ¹ , C.S. Benn ^{2,3} , P. Aaby ¹ , ¹ <i>Bandim Health Project, Guinea-Bissau</i> , ² <i>Research Center for Vitamins and Vaccines (CVIVA), Denmark</i> , ³ <i>University of Southern Denmark, Denmark</i>
[P1.06]	Influenza reverse genetics system for use in production platforms of all species B. Ramezanpour*, A.D.M.E. Osterhaus, R.A.M. Fouchier, <i>Erasmus MC, The Netherlands</i>
[P1.07]	Integrated predictive models of antibody features and effector cell functions provide insights into immune response to natural HIV infection K.G. Dowell* ¹ , E.P. Brown ¹ , A.E. Mahan ^{2,3} , A. Mikhailova ^{2,3} , G. Alter ^{2,3} , M.E. Ackerman ¹ , C. Bailey-Kellogg ¹ , ¹ <i>Dartmouth College, USA</i> , ² <i>Harvard University, USA</i> , ³ <i>Ragon Institute of Massachusetts General Hospital, USA</i>
[P1.08]	Development of an adenoviral vector vaccine for <i>Rhodococcus equi</i> infections in foals C. Giles* ^{1,2} , T. Vanniasinkam ³ , S. Ndi ¹ , M.D. Barton ^{1,2} , ¹ <i>University of South Australia, Australia</i> , ² <i>Sansom Institute, Australia</i> , ³ <i>Charles Sturt University, Australia</i>
[P1.09]	Recombinant protein LipL32 of <i>Leptospira</i> induces humoral immune response in mice by transcutaneous immunization P.S. Liu*, M.L. Vieira, A.L.T.O. Nascimento, W.O. Dias, <i>Instituto Butantan, Brazil</i>
[P1.10]	Prevalence of <i>Staphylococcus aureus</i> in marine and Farmed shrimps N. Arfatahery ^{1,2} , M. M Soltandallal* ^{1,2} , T. Abbedymotaseb ¹ , M. Zeinolabedini Zamani ^{1,2} , ¹ <i>Tehran University of Medical Sciences., Iran</i> , ² <i>School of Public Health, Iran</i>
[P1.11]	Use of yeast lysate in women with recurrent vulvovaginal candidiasis V. Vrzal*, L. Bittner, J. Nepereny, <i>Bioveta,a.s., Czech Republic</i>
[P1.12]	Antibody response of dogs after immunisation with chimeric vaccine against borreliosis J. Nepereny* ¹ , V. Vrzal ¹ , M. Raska ² , E. Weigl ² , M. Krupka ² , J. Turanek ³ , J. Masek ³ , ¹ <i>Bioveta, a.s., Czech Republic</i> , ² <i>Palacký University Olomouc, Czech Republic</i> , ³ <i>Veterinary research institute, Czech Republic</i>
[P1.13]	High throughput, automated analytics to support vaccine process and formulation development P.M. Egan* ¹ , J. Acevedo-Skrip ¹ , A.M. Bowman ¹ , D. Cole-Novak ¹ , L. Denny ¹ , S. Di ¹ , K.M. Krach ¹ , P. Moravec ¹ , K. Kearns ¹ , P. DePhillips ¹ , ¹ <i>Merck Research Laboratories, USA</i> , ² <i>Lancaster Laboratories, USA</i>
[P1.14]	Fine-tuning of host immune responses: A tale of Adeno-vector expressing Hepatitis C virus Antigen NS4 S. Singh*, W. Li, R. Kumar, B. Agrawal, <i>University of Alberta, Canada</i>
[P1.15]	Immunization with a formalin-inactivated Enterovirus 71 whole virion vaccine elicits a long-term cross-neutralizing antibody response in monkeys C.C. Liu* ¹ , C.S. Hwang ² , W.S. Yang ¹ , D.C. Tsai ¹ , S.H. Wu ¹ , A.H. Chou ¹ , Y.H. Chow ¹ , S.C. Wu ³ , J.R. Wang ¹ , J.R. Chiang ⁴ , ¹ <i>National Institute of Infectious Diseases and Vaccinology, NHRI, Taiwan</i> , ² <i>Animal Health Research Institute, Taiwan</i> , ³ <i>Institute of Biotechnology, NTHU, Taiwan</i> , ⁴ <i>Centers for Disease Control, Taiwan</i>
[P1.16]	Elimination plan of measles in Canary Island 2001-2013 A. García Rojas* ¹ , P. Garcia Castellan ¹ , P. Matute Cruz ¹ , A. Nuñez Gallo ¹ , N. Abadia Jimenez ¹ , D. Trujillo Herrera ¹ , J. Solis Romero ¹ , M.C. Perez Gonzalez ² , F. Artiles Campelo ¹ , ¹ <i>Public Health Service, Spain</i> , ² <i>Microbiology Service. Gran canary Hospital, Spain</i>

[P1.17]	Social networks and HPV coverage. 2008-2013 A. García Rojas*, P. Garcia Castellano, P. Matute Cruz, D. Nuñez Gallo, D. Trujillo Herrera, J. Solis Romero, <i>Public health Service, Spain</i>
[P1.18]	Improvement of hepatitis B virus DNA vaccines by dissolving microneedle arrays Y.Q. Qiu* ¹ , L. Guo ¹ , Y.H. Gao ¹ , P.Y. Mao ² , ¹ <i>Chinese Academy of Sciences, China</i> , ² <i>302 Military Hospital of China, China</i>
[P1.19]	Rate of co-colonization with serotypes of Streptococcus Pneumoniae isolated from nasopharyngeal swab in healthy children less than 2 years in Tehran S. Rafiei Tabatabaei* ¹ , A. Karimi ¹ , F. Fallah ¹ , F. Shiva ¹ , M.M. Gooya ² , M. Zahraei ² , ¹ <i>Shahid Beheshti University of Medical Sciences, Iran</i> , ² <i>Ministry of Health and Medical Education, Iran</i>
[P1.20]	Multiplex PCR assay for detection of pneumococcal serotypes in nasopharyngeal samples of healthy children; Tehran, 2009-2010 S. Rafiei Tabatabaei* ¹ , F. Fallah ¹ , F. Shiva ¹ , A.R. Shamshiri ² , M. Hajia ³ , M. Navidinia ¹ , A. Karimi ¹ , M. Rahbar ^{3,4} , ¹ <i>Shahid Beheshti University of Medical Sciences, Iran</i> , ² <i>Tehran University of Medical Sciences, Iran</i> , ³ <i>Ministry of Health and Medical Education, Iran</i> , ⁴ <i>Iran University of Medical sciences, Iran</i>
[P1.21]	Serological immune responses against NSP residues in FMD trivalent vaccine after multiple vaccination in cattle, pigs and goats M.G. Seo*, H.S. Lee, Y.J. Ko, J.E. Chun, S.M. Kim, K.N. Lee, J.H. Park, B. Kim, D.S. Tark, <i>Animal and Plant Quarantine Agency, Republic of Korea</i>
[P1.22]	Evaluation of the experimental foot-and-mouth disease vaccine using new Oil/Gel adjuvant mixtures in pigs and goats M.E. Park ^{1,3} , S.Y. Lee ^{1,3} , R.H. Kim ¹ , M.K. Ko ¹ , K.N. Lee ¹ , S.M. Kim ¹ , B.K. Kim ² , J.S. Lee ³ , B. Kim* ¹ , J.H. Park ¹ , ¹ <i>Animal and Plant Quarantine Agency, Republic of Korea</i> , ² <i>MJ Biologics, USA</i> , ³ <i>Chungnam National University, Republic of Korea</i>
[P1.23]	Functional imbalance of neurons in the central nervous system caused by astrocytes infected with enterovirus 71 S. Guo, Y. Zhang, M. Feng*, N. Ma, Y.C. Che, L.C. Wang, Y. Liao, L.D. Liu, J.J. Wang, Q.H. Li, <i>Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, China</i>
[P1.24]	The structure, pathogenicity and immunogenicity of two virion fractions harvested from cell cultures infected with the CA16 virus J. Pu*, H.T. Huang, Y. Zhang, M. Feng, E.X. Yang, Y.C. Che, C.H. Dong, Y. Liao, L.D. Liu, L.C. Wang, <i>Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, China</i>
[P1.25]	Removal of natural anti-galactose α1,3 galactose antibodies with GAS914 enhances humoral immunity and prevents sepsis mortality in α1,3 galactosyltransferase knockout mice R. Manez* ^{1,2} , M. Perez-Cruz ² , D. Bello ² , C. Costa ² , ¹ <i>Bellvitge University Hospital, Spain</i> , ² <i>Bellvitge Biomedical Research Institute (IDIBELL), Spain</i>
[P1.26]	Recombinant rabies virus particles presenting Botulinum neurotoxin antigens elicit protective humoral responses in vivo A.W. Hudacek* ^{1,2} , F. Al-Saleem ³ , M. Willet ² , T. Eisemann ² , J. Mattis ¹ , L.L. Simpson ³ , M.J. Schnell ² , ¹ <i>Molecular Targeting Technologies, Inc., USA</i> , ² <i>Thomas Jefferson University, USA</i> , ³ <i>Inventox, Inc., USA</i>
[P1.27]	Changing T cell epitopes; A mumpsvirus case study E.J. Homan*, R.D. Bremel, <i>Eigenbio LLC, USA</i>
[P1.28]	Vaccine Associated Paralytic Poliomyelitis (VAPP) with OPV in India: Red alert safety concern! J.L. Mathew* ¹ , S.K. Mittal ² , ¹ <i>Postgraduate Institute of Medical Education and Research, India</i> , ² <i>Pushpanjali Crosslay Hospital, India</i>
[P1.29]	Evaluation of immunogenicity and cross-protective efficacy of MVATM-based universal influenza vaccine candidates in mice against H1N1, H5N1 and H7N9 influenza strains S. Auer, F.P. Wachs, M. Skiadopoulos, N. Mytle, J.W. Jackson, S. Leyrer*, <i>Emergent BioSolutions Inc., Rockville, Maryland, USA</i>
[P1.30]	Protective immunogenicity of rsv-vaccine candidates based on the modified vaccinia virus Ankara (mva) platform technology in mice F.P. Wachs ¹ , K. Kindsmueller* ¹ , U. Power ¹ , M. Skiadopoulos ¹ , J.W. Jackson ¹ , S. Leyrer ¹ , ¹ <i>Emergent BioSolutions Inc., USA</i> , ² <i>Queen's University, UK</i>
[P1.31]	Optimal timing of the second dose of varicella vaccine to prevent secondary vaccine failure in Japan: Assessment by varicella zoster virus (VZV) skin test and IAHA and gp-ELISA antibody assay M. Ohashi* ^{1,2} , H. Miura ¹ , F. Iida ¹ , E. Matsuoka ¹ , Y. Kawamura ¹ , H. Ando ² , T. Yoshikawa ¹ , ¹ <i>Fujita Health University School of Medicine, Japan</i> , ² <i>Toyokawa Municipal Hospital, Japan</i>

[P1.32]	<p>Is there a justification for universal Pneumococcal vaccination in India? Preliminary data from Community Acquired Pneumonia Etiology Study (CAPES) J.L. Mathew*¹, S.C. Singhi¹, P. Ray¹, B.V. Ravi Kumar², E. Hagel³, A. Nilsson³, ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Xcyton Diagnostics Pvt Ltd, Bangalore, India, ³Karolinska University Hospital, Stockholm, Sweden</p>
[P1.33]	<p>Analysis of single nucleotide polymorphism among Varicella-Zoster virus and identification of vaccine-specific sites Y.H. Won*¹, I.K. Kim¹, J.I. Kim¹, W.J. Lee², S-G. Kim², C.H. Lee¹, ¹Chungbuk National University, Republic of Korea, ²Mogam Biotechnology Research Institute, Republic of Korea</p>
[P1.34]	<p>Hospitalizations with influenza in the northern hemisphere 2013-2014 influenza season. Results from the global influenza hospital surveillance network J. Puig-Barberà*¹, A. Tormos¹, S. Trushakova², A. Sominina³, M. Pisareva³, M.A. Ciblak⁴, L. Feng⁵, Y. Qin⁵, E. Burtseva², ¹Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Spain, ²D.I. Ivanovsky Institute of Virology, Russia, ³Research Institute of Influenza, Russia, ⁴National Influenza Reference Laboratory Capa-Istanbul, Turkey, ⁵Chinese Center for Disease Control and Prevention, China</p>
[P1.35]	<p>Respiratory virus admissions in children under five years of age during three consecutive seasons J. Puig-Barberà*^{1,2}, R. Larrea-González³, M. Carballido-Fernández³, R. Limón-Ramírez⁴, M. Tortajada-Girbés⁵, M.C. Otero-Reigada⁶, J. Mollar-Maseres⁶, C. Carratalá-Munuera⁷, V. Gil-Guillén⁷, P. Correcher-Medina⁸, ¹FISABIO-Public Health, Spain, ²Centro de Salud Pública de Castellón, Spain, ³Hospital General de Castellón, Spain, ⁴Hospital La Plana, Spain, ⁵Hospital Doctor Peset, Spain, ⁶Hospital La Fe, Spain, ⁷Universidad Miguel Hernández, Spain, ⁸Hospital Lluís Alcanyis, Spain, ⁹Hospital General de Alicante, Spain, ¹⁰CIBERESP-Instituto de Salud Carlos III, Spain</p>
[P1.36]	<p>Hospital admissions associated to respiratory viruses in the Valencia Hospital network for the study of influenza and other respiratory viruses. Season 2013-2014 J. Puig-Barberà*^{1,2}, M. Carballido-Fernández³, R. Limón-Ramírez⁴, M. Tortajada-Girbés⁵, M.C. Otero-Reigada⁷, J. Mollar-Maseres⁷, C. Carratalá-Munuera⁶, V. Gil-Guillén⁶, A. Natividad-Sancho¹, A. Tormos¹, ¹FISABIO-Public Health, Spain, ²Centro de Salud Pública de Castellón, Spain, ³Hospital General de Castellón, Spain, ⁴Hospital La Plana, Spain, ⁵Hospital Doctor Peset, Spain, ⁶Universidad Miguel Hernández, Spain, ⁷Hospital La Fe, Spain</p>
[P1.37]	<p>Influenza vaccine effectiveness to prevent admissions with influenza in adults belonging to target groups for vaccination in the Valencia Hospital Network. A test-negative, hospital-based, study, 2013-2014 influenza season J. Puig-Barberà*^{1,2}, M. Carballido-Fernández³, R. Limón-Ramírez⁴, M. Tortajada-Girbés⁵, M.C. Otero-Reigada⁶, J. Mollar-Maseres⁶, C. Carratalá-Munuera⁷, V. Gil-Guillén⁷, A. Natividad-Sancho¹, A. Tormos¹, ¹FISABIO-Public Health, Spain, ²Centro de Salud Pública de Castellón, Spain, ³Hospital General de Castellón, Spain, ⁴Hospital La Plana, Spain, ⁵Hospital Doctor Peset, Spain, ⁶Hospital La Fe, Spain, ⁷Universidad Miguel Hernández, Spain, ⁸CIBERESP-Instituto de Salud Carlos III, Spain</p>
[P1.38]	<p>WITHDRAWN</p>
[P1.39]	<p>Does vaccination date affect influenza vaccine effectiveness? Valencia Hospital Network, hospital-based, test-negative, study in two consecutive influenza seasons J. Puig-Barberà*^{1,2}, A. Mira-Iglesias¹, J. Libroero-López¹, M. Carballido-Fernández³, R. Limón-Ramírez⁴, M. Tortajada-Girbés⁵, M.C. Otero-Reigada⁶, J. Mollar-Maseres⁶, C. Carratalá-Munuera⁷, V. Gil-Guillén⁷, ¹FISABIO-Public Health, Spain, ²Centro de Salud Pública de Castellón, Spain, ³Hospital General de Castellón, Spain, ⁴Hospital La Plana, Spain, ⁵Hospital Doctor Peset, Spain, ⁶Hospital La Fe, Spain, ⁷Universidad Miguel Hernández, Spain, ⁸CIBERESP-Instituto de Salud Carlos III, Spain</p>
[P1.40]	<p>An MVA based yellow fever vaccine candidate offers a safe alternative to replicating 17D yellow fever vaccines M. Testori*¹, J. Julander², C. Cheminay¹, A. Volkman¹, P. Chaplin¹, ¹Bavarian Nordic GmbH, Germany, ²Utah State University, USA</p>
[P1.41]	<p>Impact of gender-specific human papillomavirus vaccination recommendations on coverage of other adolescent vaccines R.A. Bednarczyk*, W.A. Orenstein, S.B. Omer, Emory University, USA</p>
[P1.42]	<p>COBRA HA elicited broadly reactive antibodies neutralize antigenically diverse H3N2 isolates and protects against antigenic drift. T.M. Wong*¹, H. Kleanthous², T. Alefantis², M. Parrington², D.M. Carter¹, T.M. Ross¹, ¹Vaccine and Gene Therapy Institute of Florida, USA, ²Sanofi-Pasteur, Inc., USA</p>

[P1.43]	Novel modification and combination of peptides from multiple tumour antigens enhances peptide activated T cell responses. P.L. Smith*, R. Sultan, A. Dalgleish, <i>St Georges University of London, UK</i>
[P1.44]	Attenuation mutations for Rift Valley fever virus MP-12 vaccine T. Ikegami*, T.E. Hill, O. Lihoradova, N. Lokugamage, T.L. Juelich, J.K. Smith, L. Zhang, B. Gong, A.N. Freiberg, <i>University of Texas Medical Branch, USA</i>
[P1.45]	Digital Signal Processing Techniques: Can They Analyze Vaccines Containing Mixtures of Proteins? N.I. Nwankwo, <i>Madonna University, Nigeria</i>
[P1.46]	Chemokine adjuvanted EP-DNA vaccine induces substantial protection from SIV vaginal challenge M. Wise ¹ , M. Kutzler ² , N.A. Hutnick ¹ , Z. Moldoveanu ³ , M. Hunter ⁴ , D. Montefiori ⁶ , N.Y. Sardesai ⁵ , J. Mestecky ³ , P. Marx ⁴ , D. Weiner* ¹ , ¹ <i>University of Pennsylvania, USA</i> , ² <i>Drexel University, USA</i> , ³ <i>University of Alabama, USA</i> , ⁴ <i>Tulane University, USA</i> , ⁵ <i>Inovio Pharmaceuticals, USA</i> , ⁶ <i>Duke University, USA</i>
[P1.47]	Transmitter founder multi-envelope DNA vaccine induces potent cross-clade cellular and humoral responses in rabbits and non-human primates M. Wise ¹ , K. Muthumani ¹ , J.M. Mendoza ² , D. Montefiori ³ , C. Labranche ³ , K.E. Broderick ² , M. Morrow ² , N.Y. Sardesai ² , D. Weiner* ¹ , ¹ <i>University of Pennsylvania, USA</i> , ² <i>Inovio Pharmaceuticals, USA</i> , ³ <i>Duke University, USA</i>
[P1.48]	Genetic Stability of Rift Valley fever virus MP-12 vaccine and the NSs mutant in Vero Cells N. Lokugamage*, T. Ikegami, <i>The University of Texas Medical Branch, USA</i>
[P1.49]	A recombinant chimera containing the C- and N-terminal moieties of the Nucleoside Hydrolase (NH36) of <i>Leishmania (L.) donovani</i> prophylaxis of mice against <i>Leishmania (L.) infantum</i> infection. D.C. Gomes, D. Nico, C.B. Palatnik-de-Sousa*, <i>Universidade Federal do Rio de Janeiro, Brazil</i>
[P1.50]	Missed opportunities for Human Papillomavirus (HPV) vaccination B.J. Dorton* ¹ , A.F. Vitonis ¹ , S. Feldman ^{1,2} , ¹ <i>Brigham and Women's Hospital, Boston, MA, USA</i> , ² <i>Dana Farber Cancer Institute, Boston, MA, USA</i>
[P1.51]	Prophylactic effect of H5N1 influenza vaccine based on vaccinia virus vector in cynomolgus monkeys F. Yasui* ¹ , K. Munekata ¹ , Y. Itoh ² , T. Fujiyuki ³ , T. Kuraishi ³ , Y. Sakoda ⁴ , M. Yoneda ³ , H. Kida ⁴ , C. Kai ³ , K. Ogasawara ² , M. Kohara ¹ , ¹ <i>Tokyo Metropolitan Institute of Medical Science, Japan</i> , ² <i>Shiga University of Medical Science, Japan</i> , ³ <i>The Institute of Medical Science, The University of Tokyo, Japan</i> , ⁴ <i>Hokkaido University, Japan</i>
[P1.52]	Immunostimulatory and Conventional Liposome Adjuvants Induce Distinct Differences in the Magnitude, Quality and Kinetics of Innate and Adaptive Immune Responses. S. Faisal* ^{1,2} , J. Scaria ² , Y-F. Chang ² , ¹ <i>National Institute of Animal Biotechnology, India</i> , ² <i>Cornell University, USA</i>
[P1.53]	Development of a contraceptive rabies vaccine for dogs M. Faber, <i>Thomas Jefferson University, USA</i>
[P1.54]	Characterization of Phenotype cells Markers by Immunohistochemistry in mice immunized with <i>Neisseria meningitidis</i> B (OMVs) with Cationic Lipid (DDA-BF) compared with Alum. L. Brito ¹ , E. Nogueira ¹ , R. Brasil ¹ , E. Gaspar ¹ , N. Lincopam ¹ , E. De Gaspari* ¹ , ¹ <i>Adolfo Lutz Institute, Brazil</i> , ² <i>Adolfo Lutz Institute, Brazil</i> , ³ <i>Adolfo Lutz Institute, Brazil</i> , ⁴ <i>Embrapa Southern Region Animal Husbandry, Brazil</i> , ⁵ <i>Institute of Biomedical Sciences, Department of Microbiology, University of São Paulo, São Paulo/SP, Brazil</i> , ⁶ <i>Adolfo Lutz Institute, Brazil</i>
[P1.55]	Enhanced protection against other Flaviviruses in C57BL/6 mice immunized with a serum-free Vero cell-derived Japanese encephalitis vaccine combined with Advax™ delta inulin adjuvant H. Toriniwa* ¹ , N. Petrovsky ² , T. Komiya ¹ , ¹ <i>The Kitasato Daiichi Sankyo Vaccine Co., LTD., Japan</i> , ² <i>Flinders Medical Centre/Flinders University, Australia</i>
[P1.56]	WITHDRAWN
[P1.57]	Nonclinical pharmacology for new generations of vaccines: a regulatory perspective M. Van Damme*, P. Beukelaers, L. Segal, <i>GSK Vaccines, Belgium</i>
[P1.58]	H5N1 vaccination boosts broadly neutralizing influenza virus hemagglutinin stalk-reactive antibodies in humans R. Nachbagauer* ¹ , T.J. Wohlbold ^{1,2} , A. Hirsh ¹ , R. Hai ¹ , H. Sjursen ^{3,4} , P. Palese ^{1,5} , R. Cox ^{4,6} , F. Krammer ¹ , ¹ <i>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA</i> , ² <i>Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA</i> , ³ <i>The Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway</i> , ⁴ <i>Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Bergen, Norway</i> , ⁵ <i>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA</i> , ⁶ <i>Department of Research and Development, Haukeland University Hospital, Bergen, USA</i>

[P1.59]	A Novel Analytic Methodology to Assess Vaccination Timing in India N. Shrivastwa*, B. Gillespie, J.M. Lepkowski, M.L. Boulton, <i>University of Michigan, USA</i>
[P1.60]	Preclinical Development of Killed Rabies Virus Based Tetraivalent Vaccine Against Rabies and Filoviruses M. Willet ¹ , C. Wirblich ¹ , A. Papaneri ² , S. Beilfuss ³ , E. Pommerening ³ , T. Luther ³ , P. Jahrling ^{2,4} , G. Rudolph ³ , R. Johnston ^{2,4} , M.J. Schnell ^{*1} , ¹ Thomas Jefferson University, USA, ² Integrated Research Facility, NIAID, USA, ³ IDT Biologika GmbH, Germany, ⁴ Emerging Viral Pathogens Section, NIAID, USA
[P1.61]	A polyantigenic genotype 1a/1b consensus hepatitis C virus DNA vaccine induces broadly reactive HCV-specific cellular immune responses in both mice and non-human primates E.N. Gary ^{*1} , B.P. Latimer ¹ , S. Baliban ¹ , R. Toporovski ¹ , N. Sardesai ² , J.M. Jacobson ¹ , D.B. Weiner ³ , M.A. Kutzler ¹ , ¹ Drexel University College of Medicine, USA, ² Inovia Pharmaceuticals, USA, ³ University of Pennsylvania School of Medicine, USA
[P1.62]	Characterization of a virus-derived oligonucleotide with strong immunostimulatory activity J. Xu*, X. Mercado-López, Y. Sun, C.B. Lopez, <i>University of Pennsylvania, USA</i>
[P1.63]	Integrated <i>in silico</i> Prediction to Identify Vaccine Candidates against Enterohemorrhagic <i>Escherichia coli</i> O157:H7 A. Kalita ^{*1} , M. Kalita ¹ , V.A. Garcia-Angulo ² , A.G. Torres ¹ , ¹ University of Texas Medical Branch, USA, ² University Mayor, Santiago, Chile
[P1.64]	A cotton rat model for evaluation of a respiratory syncytial virus vaccine for pregnant women A. Woods*, K. Hashey, J. Monroe, K. Friedrich, P. Dormitzer, C. Shaw, <i>Novartis Vaccines, Inc., USA</i>
[P1.65]	Sublingual immunization with chimeric C1q/CD40 ligand/HIV virus-like particles (VLP) induces strong mucosal immune responses against HIV S.Z. Zhang, E.P. Poteet, F.L. Li, C.C. Chen, Q.Y. Yao*, <i>Baylor College of Medicine, USA</i>
[P1.66]	Targeting β-sheet Amyloid Oligomers by passive immunotherapy in Tg2576 mice M.J. Guerrero-Muñoz ^{*1,2} , D.L. Castillo-Carranza ^{1,2} , C. Hernandez ^{1,2} , U. Sengupta ^{1,2} , K. Dineley ^{1,2} , R. Kayed ^{2,3} , ¹ University of Texas Medical Branch, USA, ² Mitchell Center for Neurodegenerative diseases, USA, ³ Sealy Center for Vaccine development, USA
[P1.67]	Development of a chemically defined, bioreactor-optimized, cell culture media for dengue vaccine production and confirmation of vaccine efficacy in mice B. Tarbet ^{*1} , G. Patel ² , M. Szczypka ² , C. Huang ³ , S. Pettit ⁴ , ¹ Utah State University, USA, ² SoloHill Engineering, USA, ³ Centers for Disease Control and Prevention, USA, ⁴ InVitria, USA
[P1.68]	Stabilization of Outer Domain of gp120 from HIV-1 Subtype C for Vaccine Immunogen Design J. Thompson ¹ , P. Kumar ¹ , J. Yi ² , D. Bowder ¹ , C. Wood ¹ , S.H. Xiang ^{*1} , ¹ University of Nebraska-Lincoln, USA, ² Hunan Institute of Science and Technology, China
[P1.69]	CCR10 expression is required for the immunogenicity of HIV-1env DNA Vaccines encoding the molecular adjuvant CCL28 to enhance HIV-1env-specific IgG and IgA M.A. Kutzler ^{*1} , N. Kathuria ¹ , K. Muthumani ⁴ , M. Wise ⁴ , Z. Moldoveanu ⁵ , A.S. Khan ² , N.Y. Sardesai ² , J. Mestecky ⁵ , P. Marx ³ , D.B. Weiner ⁴ , ¹ Drexel University College of Medicine, USA, ² Inovia Pharmaceuticals, USA, ³ Tulane National Primate Center, USA, ⁴ University of Pennsylvania School of Medicine, USA, ⁵ University of Alabama at Birmingham, USA
[P1.70]	Seroprevalence of measles, mumps and rubella antibodies in college students in mumbai: india D. Gohil ^{*1} , S. Kothari ¹ , A. Chaudhari ² , B. Gunale ² , P. Kulkarni ² , R.A. Deshmukh ¹ , A. Chowdhary ¹ , ¹ Haffkine Institute for Training, Research and Testing, India, ² Serum Institute of India Research Foundation, India
[P1.71]	Universal H1N1 Influenza Vaccine Development: Immunological characterization of consensus HLA class II hemagglutinin epitopes derived from strains circulating between 1980 and 2011 in seasonal influenza vaccination L. Moise ^{*1,2} , H. Latimer ¹ , R. Tassone ¹ , M. Ardito ¹ , F. Terry ¹ , C. Boyle ¹ , W. Martin ¹ , A.S. De Groot ^{1,2} , ¹ EpiVax, Inc., USA, ² University of Rhode Island, USA
[P1.72]	Design and Evaluation of Vaccines with the iVAX Toolkit F. Terry ¹ , R. Martin ¹ , J. Tivin ¹ , L. Moise ^{*1,2} , W. Martin ¹ , A.S. De Groot ^{1,2} , ¹ EpiVax, Inc., USA, ² University of Rhode Island, USA
[P1.73]	Trends in measles vaccination in Shanghai, China, between 2000 and 2014 A.L. Wagner ^{*1} , X. Sun ² , Z. Huang ² , J. Ren ¹ , M.L. Boulton ¹ , ¹ University of Michigan, Ann Arbor, USA, ² Shanghai CDC, China
[P1.74]	In silico prediction of T cell epitope cross-reactivity with JanusMatrix F. Terry ¹ , A. Gutiérrez ² , L. Moise ^{*1,2} , R. Liu ² , R. Tassone ² , C. Bailey-Kellogg ³ , W. Martin ¹ , A.S. De Groot ^{1,2} , ¹ EpiVax, Inc., USA, ² University of Rhode Island, USA, ³ Dartmouth College, USA

[P1.75]	Designing a molecular nanovaccine against shrimp white spot syndrome virus Y. Phanse*, D. Loy, S. Puttamreddy, J. Ramirez, K. Ross, B. Narasimhan, L. Bartholomay, <i>Iowa State University, USA</i>
[P1.76]	A prophylactic human cytomegalovirus vaccine to prevent congenital infection using enveloped virus-like-particles (eVLPs) induces potent immunity greater than natural infection M. Kirchmeier, D.E. Anderson*, <i>VBI Vaccines, USA</i>
[P1.77]	Novel DNA Vaccination Against a Tyrosinase (Tyr) Mediates Protection And Targets Myeloid Derived Suppressor Cells in a Syngeneic Murine Model J. Yan* ¹ , C. Lucke ¹ , E. Reuschel ¹ , K. Ugen ² , N. Sardesai ³ , J.J. Kim ³ , D. Weiner ¹ , K. Muthumani ¹ , ¹ <i>University of Pennsylvania School of Medicine, USA</i> , ² <i>University of South Florida College of Medicine, USA</i> , ³ <i>Inovio Pharmaceuticals, USA</i>
[P1.78]	Time-to-infection by genuine human papillomaviruses H-K Wang*, Q. Wei, Z. Moldoveanu, W. Huh, H. Lan Vu, T.R. Broker, J. Mestecky, L.T. Chow <i>University of Alabama at Birmingham, USA</i>
[P1.79]	A novel Epstein-Barr virus gp350/220-based virus-like particle vaccine candidate for prevention of EBV infection J.G. Ogembo* ¹ , M.R. Murawski ³ , L.R. McGinnes ¹ , R. Sutiwisesak ¹ , R.W. Finberg ¹ , T. Morrison ¹ , J.D. Fingerroth ^{1,2} , ¹ <i>University of Massachusetts Medical School, USA</i> , ² <i>Beth Israel Deaconess Medical Center, USA</i> , ³ <i>Harvard Medical School, USA</i>

Poster Session 2
Monday 27 October, 15:00-16:00

[P2.01]	Deep Sequencing Along the Lineage of the Yellow Fever Vaccine Strain 17D Reveals Low Diversity and Population Stability for Primary and Secondary Seed Lots A.S. Beck*, R.B. Tesh, S.G. Widen, T.G. Wood, J. Thompson, A.D.T. Barrett, <i>University of Texas Medical Branch, USA</i>
[P2.02]	A multivalent TB vaccine targeting the esx gene family generate potent and broad cell-mediated protective immunity D.O.V. Villarreal*, J.N.W. Walters, D.B.W. Weiner, <i>University of Pennsylvania, USA</i>
[P2.03]	Human immune responses to H. pylori HLA class II epitopes identified by immunoinformatic methods S. Zhang ¹ , J. Desrosiers ² , L.D. Fast ^{1,2} , F. Terry ¹ , W.D. Martin ¹ , A.S. De Groot ^{2,3} , S.F. Moss ¹ , L. Moise* ^{2,3} , ¹ <i>Brown University, USA</i> , ² <i>University of Rhode Island, USA</i> , ³ <i>EpiVax, Inc., USA</i>
[P2.04]	Construction and synergistic effect of recombinant yeast co-expressing pig IL-2/4/6 and fusion defensin on immunity of piglets to PRRS vaccination G.M. Luo ¹ , X.P. Wan ¹ , G. Liang ² , L.Y. Yang ¹ , B. Wang ² , J.L. Chen ¹ , K. Zeng ² , X.B. Lu ² , Z.Z. Wang ³ , R. Gao* ¹ , ¹ <i>Life Science College, Sichuan University, China</i> , ² <i>Sichuan Academy of Animal Science, China</i> , ³ <i>Center for Animal Disease Control of Sichuan Province, China</i>
[P2.05]	PigMatrix vs. FluSureXP: Live Challenge Validation of a Pig Vaccine Design Tool A.H. Gutierrez* ¹ , C. Loving ² , Z. Olson ² , A. Vincent ² , F. Terry ³ , L. Moise ^{1,3} , W.D. Martin ³ , A.S. De Groot ^{1,3} , ¹ <i>University of Rhode Island, USA</i> , ² <i>USDA ARS, USA</i> , ³ <i>EpiVax Inc., USA</i>
[P2.06]	Delivery of Antibody-Encoding DNA Plasmids Protect Mice From Lethal Challenge With Chikungunya Virus P. Block, <i>University of Pennsylvania School of Medicine, USA</i>
[P2.07]	Predicting Vaccine Efficacy for Food Animals The Epitope Content Comparison (EpiCC) Tool: Application to PRRSv A.H. Gutierrez* ¹ , C. Loving ² , L. Moise ^{1,3} , W.D. Martin ³ , A.S. De Groot ^{1,3} , ¹ <i>University of Rhode Island, USA</i> , ² <i>USDA ARS, USA</i> , ³ <i>EpiVax Inc., USA</i>
[P2.08]	Careful selection of T Cell Epitopes for Improved Immunogenicity of a Candidate Multipathogen Biodefense Vaccine R. Liu* ¹ , J. Desrosiers ¹ , W.D. Martin ² , K. Sangare ¹ , R. Tassone ¹ , L. Moise ^{1,2} , A.S. De Groot ^{1,2} , ¹ <i>University of Rhode Island, USA</i> , ² <i>EpiVax Inc., USA</i>
[P2.09]	Cloning of interleukin-15 gene of Tibetan pig and adjuvant effect of its recombinant plasmids packed with PEG and PEI modified chitosan nanoparticles on immunity of mice to FMD vaccination X.P. Wan* ¹ , X. Yang ¹ , G. Liang ² , J.C. Chen ¹ , K. Zeng ² , Y. Gu ² , Z.Z. Wang ³ , R. Liu ² , X.B. Lu ² , R. Gao ¹ , ¹ <i>Life Science College, Sichuan University, China</i> , ² <i>Sichuan Academy of Animal Science, China</i> , ³ <i>Center for Animal Disease Control of Sichuan Province, China</i>

[P2.10]	Nucleic acid impurity reduction in cell-based influenza vaccine processes T. Elich, <i>EMD Millipore Corporation, USA</i>
[P2.11]	A Novel Consensus DNA Vaccine Induces Protective Immunity Against Middle East Respiratory Syndrome Coronavirus D. Weiner, <i>University of Pennsylvania School of Medicine, USA</i>
[P2.12]	Priming of CD8 T cells by adenoviral vectors is critically dependent on B7 and dendritic cells, but only partially dependent on CD28 ligation on CD8 T cells K.N. Nielsen, M.A. Steffensen, J.P. Christensen, A.R. Thomsen*, <i>University of Copenhagen, Denmark</i>
[P2.13]	Immunogenicity of Novel DNA Vaccine Encoding Leptospiral Protein LipL45 P. Vijayachari ² , N. Muruganatham* ² , K. Vedhagiri ² , K.I. Chaiithanya ² , K.K. Mathur ³ , K. Muthumani ¹ , ¹ <i>University of Pennsylvania School of Medicine, USA</i> , ² <i>Indian Council of Medical Research, India</i> , ³ <i>KIIT University, India</i>
[P2.14]	Evaluation of High risk-Human papillomavirus types distribution in patients with cervical adenocarcinoma from State of Pernambuco-Brazil. P. Souza* ¹ , T. Lubamdo ² , A. da Silva ¹ , E. Santos ¹ , M. Maia ¹ , A. Souza ² , ¹ <i>Universidade Federal Rural de Pernambuco, Brazil</i> , ² <i>Instituto Materno Infantil de Pernambuco, Brazil</i>
[P2.15]	Vaccination with recombinant influenza virus neuraminidase provides protection against homologous and heterologous – but not heterosubtypic – viral challenge T.J. Wohlbold* ^{1,2} , R. Nachbagauer ¹ , A. Hirsh ¹ , R. Cox ^{3,4} , P. Palese ^{1,6} , F. Krammer ¹ , ¹ <i>Icahn School of Medicine at Mount Sinai, USA</i> , ² <i>Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, USA</i> , ³ <i>The Influenza Centre, Department of Clinical Science, University of Bergen, Norway</i> , ⁴ <i>Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Norway</i> , ⁵ <i>Department of Research and Development, Haukeland University Hospital, Norway</i> , ⁶ <i>Department of Medicine, Icahn School of Medicine at Mount Sinai, USA</i>
[P2.16]	Enhancement of immune response in a DNA immunization against Smallpox O. Martinez* ¹ , M. Ramirez ¹ , S. Santos ¹ , E. Miranda ^{1,3} , T. Sanchez ² , C. Rivera ² , L. Vazquez ² , R. Rodriguez ² , E. Rios ³ , M. Otero ¹ , ¹ <i>University of Puerto Rico-MSC, Puerto Rico</i> , ² <i>University of Puerto Rico-RP, Puerto Rico</i> , ³ <i>Universidad Central del Caribe, Puerto Rico</i>
[P2.17]	WITHDRAWN
[P2.18]	Involvement of the AIM2 inflammasome pathway in antigen specific antibody responses elicited by HA-expressing influenza DNA vaccine J. Suschak*, S. Wang, K.A. Fitzgerald, S. Lu, <i>University of Massachusetts Medical School, USA</i>
[P2.19]	WITHDRAWN
[P2.20]	HFMD, a growing problem in Asia-Pacific D.M. Lawrence*, J. Cardoso, <i>Sentinext, Malaysia</i>
[P2.21]	Production of bacterial polysaccharides by rapid novel scalable processes S. Sharma*, N. Kumar, N. Joshi, S. Hanif, R. Rana, M.K. Chhikara, Z. Israel, <i>MSD-Wellcome Trust Hilleman Laboratories Private Limited, 2nd floor, nanotechnology building, Jamai Hamdard, new Delhi-110062, India</i>
[P2.22]	A Time-dependent Colour Changing Vaccine Indicator Reminder (VIR) Band R. Tahir* ¹ , N.S. Rakhshani ¹ , M.I. Khan ¹ , Z.A. Bhutta ² , G. Mustafa ¹ , ¹ <i>Trust for Vaccines & Immunization, Pakistan</i> , ² <i>Aga Khan University, Pakistan</i>
[P2.23]	Overcoming the cold chain: designing a thermo-stable vaccine A. Sorayya ¹ , M. Mosharrafi* ^{1,2} , R. Nayar ^{1,2} , ¹ <i>Engimata Inc., USA</i> , ² <i>HTD Biosystems Inc., USA</i>
[P2.24]	Vaccine self-assembling immune matrix (VacSIM™) is a non-viral delivery platform that augments responses to recombinant protein vaccines L.M. Shollenberger* ¹ , R.F.Q. Grenfell ² , E.F. Samli ¹ , D.A. Harn ¹ , ¹ <i>University of Georgia, USA</i> , ² <i>Oswaldo Cruz Foundation, Brazil</i>
[P2.25]	Vaccine potential of co-formulations of <i>M. bovis</i> BCG with plasmid DNA based sub-unit vaccines in small and large animal models N. Bruffaerts ¹ , M. Romano* ¹ , L. Eggers Pedersen ² , G. Vandermeulen ³ , V. Pr�at ³ , O. Denis ¹ , F. Jurion ¹ , N. Stockhofe-Zurwieden ⁴ , K. Huygen ¹ , ¹ <i>Scientific Institute of Public Health, Communicable and Infectious Diseases, Immunology, Belgium</i> , ² <i>Section for Immunology and Vaccinology, Technical University of Denmark, Denmark</i> , ³ <i>Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, UCL, Belgium</i> , ⁴ <i>Central Veterinary Institute, Part of Wageningen University&Research; Division Infection Biology, The Netherlands</i>

[P2.26]	<p>Inflammatory power and adjuvant potential of synthetic glycolipids homologous to mycolate esters of <i>M. tuberculosis</i> G. Tima¹, M. Romano*¹, O. Denis¹, S. De Prins¹, C. Van Den Poel¹, M.O. Mohsin², M.S. Baird², K. Huygen¹, ¹Scientific Institute of Public Health, Communicable and Infectious Diseases, Immunology, Belgium, ²School of Chemistry, Bangor University, Bangor, LL57 2UW Wales, UK</p>
[P2.27]	<p>The application of a proteoliposome adjuvant-system in the development of a <i>Campylobacter jejuni</i> vaccine B. Rickaby*¹, N.F. Eng³, A. Flint², A. Stintzi², F. Diaz-Mitoma^{1,3}, ¹Laurentian University, Canada, ²University of Ottawa, Canada, ³Advanced Medical Research Institute of Canada, Canada</p>
[P2.28]	<p>Flagellin as an effective adjuvant for anti-asthma vaccines and immunotherapeutics J-U. Shim¹, S.E. Lee¹, W. Hwang², C. Lee², J-W. Park³, J.H. Nam¹, Y. Kim¹, S-H. Im⁴, Y-I. Koh¹, J.H. Rhee*¹, ¹Chonnam National University, Republic of Korea, ²Gwangju Institute of Science and Technology, Republic of Korea, ³Yonsei University, Republic of Korea, ⁴Academy of Immunology and Microbiology (AIM), Institute for Basic Science (IBS) and POSTECH, Republic of Korea</p>
[P2.29]	<p>Pneumococcal surface protein A (pspA) loaded PGA-co-PDL polymeric nanocarriers formulated as nanocomposite microparticles for pulmonary vaccine delivery N.K. Kunda*¹, S. Somavarapu², G.A. Hutcheon¹, I.Y. Saleem¹, ¹Liverpool John Moores University, UK, ²University College London, UK</p>
[P2.30]	<p>Dengue virus specific MHC class I epitopes restricted to multiple alleles induce CD8+ T cell responses in seropositive individuals J.D. Comber*^{1,2}, A.A. Karabudak^{1,2}, X. Huang^{1,2}, P.A. Piazza³, E.T.A. Marques³, R. Philip^{1,2}, ¹Immunotope, Inc., USA, ²Baruch S. Blumberg Institute, USA, ³University of Pittsburgh, USA</p>
[P2.31]	<p>Human influenza viruses inactivated by hydrostatic pressure: investigating a candidate for a universal vaccine C.H. Dumard*¹, S.P.C. Barroso^{1,2}, P. Souza-Santos¹, D. Nico¹, J.L. Silva¹, ¹Federal University of Rio de Janeiro, Brazil, ²Fundação Oswaldo Cruz, Brazil</p>
[P2.32]	<p>Characterization of MHC class I presented T cell epitopes for a therapeutic vaccine against chronic HBV infection A.A. Karabudak*^{1,2}, J.D. Comber^{1,2}, V. Shetty¹, J.S. Testa¹, X. Huang^{1,2}, R. Philip^{1,2}, ¹Immunotope, Inc., USA, ²Baruch S. Blumberg Institute, USA</p>
[P2.33]	<p>A triple gene mutant of BHV-1 administered intranasally is significantly more efficacious than a BoHV-1 glycoprotein E-deleted virus against a virulent BoHV-1 challenge S. Chowdhury*, H. Wei, M. Weiss, K. Pannhorst, D. Paulsen, Louisiana State University, USA</p>
[P2.34]	<p>Production and characterization of plant expressed norovirus like particles N. Janež¹, P. Sevšek¹, D. Morisset², I. Gutierrez Aquirre², M. Ravnikar², A. Podgornik¹, M. Peterka*¹, ¹Center of excellence for biosensors, instrumentation and process control, Slovenia, ²National institute of biology, Slovenia</p>
[P2.35]	<p>Evaluation of the preclinical efficacy and safety of a Coxsackievirus B1 vaccine – implications for type 1 diabetes development P.G. Larsson¹, L. Tadepally¹, O.H. Laitinen*^{1,2}, S. Jacobsson¹, R. Utorova¹, M. Koivunen¹, N. Devard³, V. Lecouturier³, M. Knip^{4,5}, H. Hyöty^{5,6}, ¹Center for Infectious Medicine, Dept. Medicine, Karolinska Institutet, Sweden, ²Vactech Oy, Finland, ³Sanofi Pasteur, France, ⁴Children's Hospital, Univ. of Helsinki and Helsinki Univ. Central Hospital, Finland, ⁵Dept. of Pediatrics, Tampere Univ. Hospital, Finland, ⁶Dept. of Virology, Univ. of Tampere, Finland</p>
[P2.36]	<p>Vaccination with virus-like particles plus RNAdjuvant[®] induces local cytokine responses that enhance antiviral protection A. Kessler*¹, C. Soldner¹, J. Heinrich¹, S. Lienenklaus², T. Kramps³, C. Buchholz⁴, K-J. Kallen³, M. Fotin-Mlczek³, U. Kalinke¹, ¹TWINCORE, Centre for Experimental and Clinical Infection Research, Germany, ²Helmholtz Centre for Infection Research, Germany, ³CureVac GmbH, Germany, ⁴Paul-Ehrlich-Institut, Germany</p>
[P2.37]	<p>Characterization of Phenotype cells Markers by Immunohistochemistry in mice immunized with <i>Neisseria meningitidis</i> B (OMVs) with Cationic Lipid (DDA-BF) compared with Alum. L.T. Brito¹, E. Nogueira², R. Brasil², E. Gaspar³, N. Lincopan⁴, E. De Gaspari*¹, ¹Adolfo Lutz Institute, Brazil, ²Adolfo Lutz Institute, Brazil, ³Adolfo Lutz Institute, Brazil, ⁴Embrapa Southern Region Animal Husbandry, Brazil, ⁵Institute of Biomedical Sciences, Department of Microbiology, University of São Paulo, São Paulo/SP, Brazil, ⁶Adolfo Lutz Institute, Brazil</p>
[P2.38]	<p>In vivo immunogenicity of Tax 11-19 epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine. D. Sagar*¹, S. Masih¹, T. Schell², S. Jacobson³, J.D. Comber⁴, B. Wigdahl¹, R. Philip⁴, P. Jain¹, Z.K. Khan¹, ¹Drexel University College of Medicine, USA, ²Pennsylvania State University College of Medicine, USA, ³National Institutes of Health, USA, ⁴Immunotope Inc., USA</p>

[P2.39]	Lectin-targeted dendritic cell immunotherapies against multiple sclerosis. D. Sagar* ¹ , C. Foss ² , Z.K. Khan ¹ , J. Shirazi ¹ , M. Pomper ² , P. Jain ¹ , ¹ <i>Drexel University College of Medicine, USA</i> , ² <i>Johns Hopkins University, USA</i>
[P2.40]	Immunogenicity of <i>Neisseria meningitidis</i> B outer membrane vesicles (OMVs) associated with cationic lipid (DDA-BF). F. Rinaldi ¹ , L.T. Brito ¹ , E. Nogueira ² , R. Brasil ² , E. Gaspar ³ , N. Lincopan ⁴ , E. De Gaspari* ¹ , ¹ <i>Adolfo Lutz Institute, Brazil</i> , ² <i>Adolfo Lutz Institute, Brazil</i> , ³ <i>Adolfo Lutz Institute, Brazil</i> , ⁴ <i>Adolfo Lutz Institute, Brazil</i> , ⁵ <i>Embrapa Southern Region Animal Husbandry, Brazil</i> , ⁶ <i>Institute of Biomedical Sciences, Department of Microbiology, University of São Paulo, São Paulo/SP, Brazil</i> , ⁷ <i>Adolfo Lutz Institute, Brazil</i>
[P2.41]	Pulmonary antigen delivery using surface modified PGA-co-PDL nanocomposite microparticles I. Alfagih ^{1,2} , N.K. Kunda* ¹ , F. Alanazi ² , G.A. Hutcheon ¹ , I. Saleem ¹ , ¹ <i>Liverpool John Moores University, UK</i> , ² <i>King Saud University, Saudi Arabia</i>
[P2.42]	Potentiating dendritic cells to target hypoxic environment of brain tumor. R. Ginwala*, D. Sagar, S. Karakashev, Z.K. Khan, M. Reginato, P. Jain, <i>Drexel University College of Medicine, USA</i>
[P2.43]	Evaluation of Intranasal and Subcutaneous Route of Immunization with OMVs of <i>Neisseria Meningitidis</i> B Using DDA-BF as Adjuvant L.T. Brito ¹ , E. De Gaspari* ¹ , ¹ <i>Adolfo Lutz Institute, Brazil</i> , ² <i>Adolfo Lutz Institute, Brazil</i>
[P2.44]	Infection-permissive immunity provided by NA- and M2e-based vaccines protects against Influenza A virus challenge and allows the induction of heterosubtypic immunity during subsequent infections S.M. Schotsaert* ^{1,2} , Y.T. Ysenbaert ^{1,2} , S.A. Smet ^{1,2} , S.B. Schepens ^{1,2} , F.W. Fiers ^{1,2} , S.X. Saelens ^{1,2} , ¹ <i>VIB, Belgium</i> , ² <i>Ghent University, Belgium</i> , ³ <i>Icahn School of Medicine at Mount Sinai, USA</i>
[P2.45]	Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets F. Krammer, P. Palese, A. Garcia-Sastre, R. Albrecht*, <i>Icahn School of Medicine at Mount Sinai, USA</i>
[P2.46]	An assessment of adult hepatitis B vaccination rate in the primary care setting and its relationship with physician knowledge, attitudes and practices J. Radix* ¹ , R. Marks ¹ , P.J. Edelson ² , T. Tran ³ , ¹ <i>Teachers College, Columbia University, USA</i> , ² <i>Columbia University College of Physicians and Surgeons, USA</i> , ³ <i>Cedars-Sinai, USA</i>
[P2.47]	Antibody persistence in four groups of children of 6-7 years of age, 1 year later immunization with two MMR vaccines applied by aerosol or by injection J.L. Díaz-Ortega* ¹ , D. Castañeda-Desales ¹ , D.M. Arellano-Quintanilla ¹ , D. Martínez ^{1,2} , J. Fernández de Castro ¹ , ¹ <i>Instituto Nacional de Salud Pública, Mexico</i> , ² <i>Instituto Nacional de Enfermedades Respiratorias, Mexico</i>
[P2.48]	Process Development and Tech Transfer of a Novel Whole Cell Vaccine to a Developing-Country Vaccine Manufacturer S.N. Behrens* ¹ , A. Tate ² , ¹ <i>SB Executive Consulting, LLC, USA</i> , ² <i>PATH, USA</i>
[P2.49]	Vaccination in Ghana: maternal attributes and coverage D. Ansong* ¹ , D. Tawfik ² , I. Boaky ¹ , I. Nyanor ¹ , B. Arhin ¹ , J.M. Boaheng ¹ , C. Obirikorang ¹ , S. Benson ² , E.A. Williams ¹ , T. Dickerson ² , ¹ <i>Komfo Anokye Teaching Hospital, Ghana</i> , ² <i>University of Utah, USA</i>
[P2.50]	Haloarchaeal gas vesicle nanoparticles displaying <i>Salmonella</i> antigens as a novel approach to vaccine development P. DasSarma ¹ , V.D. Negi ^{2,3} , A. Balakrishnan ³ , J.M. Kim ⁴ , R. Karan ¹ , D. Chakravorty ³ , S. DasSarma* ¹ , ¹ <i>University of Maryland School of Medicine, USA</i> , ² <i>National Institute of Technology, India</i> , ³ <i>Indian Institute of Science, India</i> , ⁴ <i>PuKyong National University, Republic of Korea</i>
[P2.51]	Production And Characterization of Neutralizing Human Monoclonal Antibodies From The Cells of A(H1N1)Pdm 2009 Influenza Virus Infected Indian Donors L. Saxena*, M. Khanna, <i>VP Chest Institute, India</i>
[P2.52]	Pre-clinical development of highly immunogenic anti-survivin vaccines for mesothelioma patients P. Bertino* ¹ , F. Terry ² , M. Panigada ³ , E. Soprana ³ , L. Moise ⁴ , A. Siccardi ³ , A.S. De Groot ⁴ , P.R. Hoffmann ¹ , ¹ <i>University of Hawaii, USA</i> , ² <i>EpiVax, USA</i> , ³ <i>San Raffaele University, Italy</i> , ⁴ <i>University of Rhode Island, USA</i>
[P2.53]	Increasing Postpartum Rate of Vaccination with Tetanus, Diphtheria, and Acellular Pertussis Vaccine by Incorporating Pertussis Cocooning Information into Prenatal Education for Group B Streptococcus Prevention P-J. Cheng*, S-Y. Huang, C-L. Chang, Y-K. Soong, <i>Chang Gung Memorial Hospital, Taiwan</i>
[P2.54]	Trends in meningitis hospitalizations before and after 7-valent pneumococcal conjugate vaccine introduction in Rwanda, 2002-2012 D.C. Whitehead ¹ , L. Nyirazinyoye ² , J. Omolo ² , V. Ndahindwa ² , M. Gatera* ³ , ¹ <i>Geisel School of Medicine at Dartmouth, USA</i> , ² <i>National University of Rwanda School of Public Health, Rwanda</i> , ³ <i>Rwanda Biomedical Center, Rwanda</i>

[P2.55]	Passive Immunotherapy Targeting Toxic Tau Protein Protects against Neurodegeneration in Mouse Model of Alzheimer's Disease J.E. Gerson, D.L. Castillo-Carranza, U. Sengupta, M.J. Guerrero-Muñoz, R. Kaye*, <i>University of Texas Medical Branch, USA</i>
[P2.56]	Whole Genome Sequencing of Brazilian Pertussis Vaccine Strain and Virulence Factors Characterization M.A. Akamatsu ^{*1} , M.Y. Nishiyama-Jr ¹ , J.P.F.W. Kitajima ² , M. Morone ¹ , U.C. Oliveira ¹ , M.F. Sakauchi ¹ , I. Raw ¹ , I.L.M. Junqueira de Azevedo ¹ , E. Carvalho ¹ , P.L. Ho ¹ , ¹ <i>Instituto Butantan, Brazil</i> , ² <i>Mendelics Análise Genômica, Brazil</i>
[P2.57]	Investigating <i>i.n</i> immunization with a rMVA vaccine and the induction of gastro-intestinal immune responses. S-L. Sanos*, R. Kassub, J. Patzold, B. Bathke, K. Brinkmann, P. Chaplin, H. Hochrein, H. Lauterbach, <i>Bavarian Nordic GmbH, Germany</i>
[P2.58]	Improved immune stimulating activity of Alum containing Adjuvant formulation in order to enhance Leptospiral Vaccine efficacy R. Banihashemi ^{*1,4} , M. Tebianian ¹ , A.R. Jabbari ¹ , S. Jalali ² , R. Ghaderi ¹ , K. Tadayon ¹ , M. Sekhavati ¹ , E. Banihashemi ³ , ¹ <i>Razi Vaccine Serum Research Institute, Iran</i> , ² <i>Tehran Medical University, Tehran, Iran</i> , ³ <i>Iran Medical University, Iran</i> , ⁴ <i>Department of Immunology, Faculty of Medicine Tarbiat Modares University, Tehran, Iran</i>
[P2.59]	The immune response to plant-derived vaccines K.L. Hefferon, <i>Cornell University, USA</i>
[P2.60]	Factors affecting vaccine opposition among alternative health care providers S.J. Bean, <i>Oregon State University, USA</i>
[P2.61]	Guillain-Barré Syndrome after Immunization in Canadian Children (1996-2012) K.A. Top ^{*1,2} , S. Desai ³ , D. Moore ⁴ , B.J. Law ³ , W. Vaudry ^{5,6} , S.A. Halperin ^{1,2} , J.A. Bettinger ^{7,8} , ¹ <i>Dalhousie University, Canada</i> , ² <i>IWK Health Centre, Canada</i> , ³ <i>Public Health Agency of Canada, Canada</i> , ⁴ <i>Montreal Children's Hospital, Canada</i> , ⁵ <i>University of Alberta, Canada</i> , ⁶ <i>Stollery Children's Hospital, Canada</i> , ⁷ <i>University of British Columbia, Canada</i> , ⁸ <i>BC Children's Hospital, Canada</i>
[P2.62]	Bovine afferent lymph dendritic cells (ALDCs): obtention, characterization and impact of Foot-and-Mouth-Disease Virus in their maturation. V. Quattrocchi ^{*1} , J. Santamaría ³ , I. Soria ² , M. Gammella ¹ , S. Ferraris ³ , J. Carrillo ¹ , L. Vagnoni ¹ , V. Maldonado ¹ , P. Zamorano ^{1,2} , ¹ <i>INTA Castelar, Argentina</i> , ² <i>CONICET, Argentina</i> , ³ <i>Universidad Maimónides, Argentina</i>
[P2.63]	Potency Determination of the 3rd National Standard of Japanese Encephalitis Virus Vaccine for <i>in vivo</i> & <i>in vitro</i> assay M.S. Yang*, H.S. Moon, H.J. Oh, H.J. Jung, N.R. Lee, D.H. Kim, S.K. Chang, J.Y. Hong, D.K. Kim, <i>Ministry of Food and DRUG Safety, Republic of Korea</i>
[P2.64]	Optimisation of exogenous protein expression and isolation for development of vaccine candidates against <i>Burkholderia pseudomallei</i> W.T. Casey*, C. Collins, M. Callaghan, S. McClean, <i>Institute of Technology Tallaght, Ireland</i>
[P2.65]	Dengue type 1 virus monoclonal antibody cocktails for analyzing neutralizing and enhancing antibody responses in human sera A. Yamanaka ^{*1,2} , E. Konishi ^{1,2} , ¹ <i>Mahidol University, Thailand</i> , ² <i>Osaka University, Japan</i>
[P2.66]	Significant immunogenicity of lipopeptide-based anti-gonadotropin releasing hormone (GnRH) vaccine candidates C.H. Chang ^{*1} , P. Varamini ¹ , F.M. Mansfeld ¹ , M.J. D'Occhio ² , I. Toth ¹ , ¹ <i>The University of Queensland, Australia</i> , ² <i>The University Sydney, Australia</i>
[P2.67]	Moved to poster session 1 as P1.79
[P2.68]	Subunit prophylactic vaccine against <i>Burkholderia cepacia</i> complex an opportunistic pathogen of cystic fibrosis patients C. Collins ^{*1} , M. Shinoy ¹ , M. Healy ² , K. English ² , B. Mahon ² , S. McClean ¹ , ¹ <i>IT Tallaght Dublin, Ireland</i> , ² <i>N.U.I. Maynooth, Co. Kildare, Ireland</i>
[P2.69]	Excess cases of narcolepsy in children and adolescents vaccinated with an AS03 adjuvanted pandemic influenza vaccine in Germany D.F. Oberle*, U. Drechsel-Bäuerle, B. Keller-Stanislawski, <i>Paul-Ehrlich-Institut, Germany</i>
[P2.70]	Functionalized catanionic vesicles: a new platform for vaccine development K. Richard ² , L. Stocker ¹ , N. Dashaputre ¹ , A. Horn ¹ , A. Manocha ¹ , R. Ernst ² , B.J. Mann ³ , D.C. Stein ¹ , S. Vogel ² , P. DeShong ^{*1} , ¹ <i>University of Maryland, College Park, USA</i> , ² <i>University of Maryland School of Medicine, USA</i> , ³ <i>University of Virginia, USA</i> , ⁴ <i>SD Nanosciences, Inc., USA</i>

[P2.71]	WITHDRAWN
[P2.72]	Measles morbidity and immunity in Tianjin, China, 2005-2013 J.P. Montgomery* ¹ , Y. Zhang ² , B. Carlson ¹ , X. Wang ² , M.L. Boulton ¹ , ¹ University of Michigan, USA, ² Tianjin Centers for Disease Control and Prevention, China
[P2.73]	Measles case-control study in Tianjin, China 2012-2014 Y. Zhang ² , J.P. Montgomery ¹ , B.F. Carlson* ¹ , X. Wang ² , M.L. Boulton ¹ , ¹ Univeristy of Michigan School of Public Health, USA, ² Tianjin Centers for Disease Control and Prevention, China
[P2.74]	Digital Droplet PCR for Influenza Vaccine Development F. Berlanda Scorza*, A. Veach, F. Porter, M. Wilson, Novartis Vaccines, USA
[P2.75]	Detecting and preventing freezing damage to vaccines: Using the LUMiSizer in vaccine formulation development D. Thiriote, B. Hu*, D. Nawrocki, C. Mensch, L. Chen, J. Blue, Merck, USA
[P2.76]	Genetic fusions of cfaB-st toxoid, cssA/B and ItB of Enterotoxigenic Escherichia coli elicit neutralizing serum antibodies in mouse model that protect immunized animals against ETEC challenge N. Zeinalzadeh* ² , G. Gujani ¹ , A.H. Salmanian ¹ , ¹ National Institute of Genetic Engineering and Biotechnology NIGEB, Shahrak-e- Pajooheh, km 15, Tehran -Karaj Highway, Tehran, Iran, ² University of Tabriz, Iran
[P2.77]	The interaction of dendritic cells and foot-and-mouth disease virus activate ERK1/2 pathway responsible of MHC class I presentation and apoptosis C.A. Langellotti ^{1,2} , G. Cesar ³ , E. Pereyra ^{1,2} , V. Gnazzo ^{1,2} , I. Soria ^{1,2} , V. Quattrocchi* ² , M. Gammella ² , P.I. Zamorano ^{1,2} , M. Vermeulen ^{1,3} , ¹ CONICET, Argentina, ² Instituto Nacional de Tecnología Agropecuaria (INTA), Argentina, ³ Academia Nacional de Medicina, Argentina
[P2.78]	A novel Porcine Circovirus Type 2 (PCV2) peptide Based vaccine formulated in Silicon Nanoparticles (SiNP) M.D. Welsh ¹ , P. Lagan-Tregaskis ¹ , S. Doherty ¹ , N. Torabipour ² , S.R. Saffie-Siebert ² , J. McKillen ¹ , M. McMenemy* ¹ ¹ Virology Branch Agri-Food & Biosciences Institute (AFBI), UK, ² SiSaf Ltd, UK
[P2.79]	PMB and ATP as possible adjuvants in antitumoral therapy X. López*, J. Mena, D. Escrig, C. Barrientos, M. Montoya, C. Acuña-Castillo, Universidad de Santiago de Chile, Chile
[P2.80]	Intra-nasal Administration of Antigen-85B and ESAT-6 conjugated to adjuvanted Maleimide-PEG-PLGA Nanoparticles provide protection against Tuberculosis in mice H. Soni*, H. Patel, A. Ormond, J. Hanes, E. Nueremberger, Johns Hopkins School of Medicine